Important Information

This website is managed by Ultima Markets’ international entities, and it’s important to emphasise that they are not subject to regulation by the FCA in the UK. Therefore, you must understand that you will not have the FCA’s protection when investing through this website – for example:

  • You will not be guaranteed Negative Balance Protection
  • You will not be protected by FCA’s leverage restrictions
  • You will not have the right to settle disputes via the Financial Ombudsman Service (FOS)
  • You will not be protected by Financial Services Compensation Scheme (FSCS)
  • Any monies deposited will not be afforded the protection required under the FCA Client Assets Sourcebook. The level of protection for your funds will be determined by the regulations of the relevant local regulator.

Note: Ultima Markets is currently developing a dedicated website for UK clients and expects to onboard UK clients under FCA regulations in 2026.

If you would like to proceed and visit this website, you acknowledge and confirm the following:

  • 1.The website is owned by Ultima Markets’ international entities and not by Ultima Markets UK Ltd, which is regulated by the FCA.
  • 2.Ultima Markets Limited, or any of the Ultima Markets international entities, are neither based in the UK nor licensed by the FCA.
  • 3.You are accessing the website at your own initiative and have not been solicited by Ultima Markets Limited in any way.
  • 4.Investing through this website does not grant you the protections provided by the FCA.
  • 5.Should you choose to invest through this website or with any of the international Ultima Markets entities, you will be subject to the rules and regulations of the relevant international regulatory authorities, not the FCA.

Ultima Markets wants to make it clear that we are duly licensed and authorised to offer the services and financial derivative products listed on our website. Individuals accessing this website and registering a trading account do so entirely of their own volition and without prior solicitation.

By confirming your decision to proceed with entering the website, you hereby affirm that this decision was solely initiated by you, and no solicitation has been made by any Ultima Markets entity.

I confirm my intention to proceed and enter this website

Tag Archives: 嬌生

嬌生公司第四季業績優於預估,惟新年前瞻保守 

嬌生公司 (JNJ.US) 第四季度業績優於分析師預期。 該公司公佈的2023年第四季銷售額為214億美元,淨收入達41.3 億美元。每股盈餘 (EPS) 為1.70 美元,而前年同期每股盈餘是1.22 美元,當時淨收入為32.3 億美元。 不包括一次性項目,該公司最近一個季度的調整後每股盈餘為 2.29 美元。    於分拆旗下消費者保健公司 Kenvue 後,嬌生公司現在經兩個業務部門運作:創新醫學(由其製藥部門組成)和醫療技術(醫療設備事業)。 本季創新醫學收入成長 4.2%,達到 137 億美元,而醫療科技銷售額飆升 13.3%,達到 77 億美元。  嬌生公司在多種新療法獲得批准方面取得了進展,其中包括治療膀胱癌的 Balversa 藥物。 然而,該公司利潤豐厚的 Stelara 藥物最快將於 2024 年中期在歐洲面臨日益激烈的競爭。 在投資者電話會議上,執行長華金·杜阿托 (Joaquin Duato) 表示,嬌生正在尋求更多收購案,並願意考慮「多種類型的交易」。  嬌生公司 2024 年前瞻指引與 12 月預測一致。 該公司預計營運銷售額將成長 5-6%,達到 882億美元至890億美元。 對於盈利,嬌生預計調整後每股收益為 10.55-10.75 美元,較去年增長 6.4-8.4%。 該 EPS 指引與華爾街預期的 10.68 美元相同。  (嬌生公司股價月線圖)  免責聲明  本文所含評論、新聞、研究、分析、價格及其他資料只能視作一般市場資訊,僅為協助讀者瞭解市場形勢而提供,並不構成投資建議。Ultima […]